Jasper Therapeutics announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper’s Board of Directors, effective immediately. Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year. Wiggans most recently served as Chairman and CEO of Pardes Biosciences.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JSPR:
- William Blair healthcare/biotech analysts hold analyst/industry conference call
- Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023
- Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
- Jasper receives IND clearance for Phase 1b/2a study of subcutaneous briquilimab
- Jasper Therapeutics appoints Herb Cross CFO